{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:34:28Z","timestamp":1778038468409,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondsstiftelsen Oslo University Hospital"},{"name":"Department of Research and Development, Division of Emergencies and Critical Care, Oslo University Hospital"},{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"crossref","award":["31384"],"award-info":[{"award-number":["31384"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), most patients with resectable peritoneal metastases from colorectal cancer experience disease relapse. MOC31PE immunotoxin is being explored as a novel treatment option for these patients. MOC31PE targets the cancer-associated epithelial cell adhesion molecule, and kills cancer cells by distinct mechanisms, simultaneously causing immune activation by induction of immunogenic cell death (ICD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Systemic and local cytokine responses were analyzed in serum and intraperitoneal fluid samples collected the first three postoperative days from clinically comparable patients undergoing CRS-HIPEC with (<jats:italic>n<\/jats:italic>\u00a0=\u00a012) or without (<jats:italic>n<\/jats:italic>\u00a0=\u00a026) intraperitoneal instillation of MOC31PE. A broad panel of 27 pro- and antiinflammatory interleukins, chemokines, interferons, and growth factors was analyzed using multiplex technology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The time course and magnitude of the systemic and local postoperative cytokine response after CRS-HIPEC were highly compartmentalized, with modest systemic responses contrasting substantial intraperitoneal responses. Administration of MOC31PE resulted in changes that were broader and of higher magnitude compared with CRS-HIPEC alone. Significantly increased levels of innate proinflammatory cytokines, such as interleukin (IL)-6, IL-1\u03b2, and tumor necrosis factor (TNF) as well as an interesting time response curve for the strong T-cell stimulator interferon (IFN)-\u03b3 and its associated chemokine interferon gamma-induced protein\/chemokine (C-X-C motif) ligand 10 (IP-10) were detected, all associated with ICD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study revealed a predominately local rather than systemic inflammatory response to CRS-HIPEC, which was strongly enhanced by MOC31PE treatment. The MOC31PE-induced intraperitoneal inflammatory reaction could contribute to improve remnant cancer cell killing, but the mechanisms remain to be elucidated in future studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-021-10022-0","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T15:03:00Z","timestamp":1621609380000},"page":"5252-5262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy"],"prefix":"10.1245","volume":"28","author":[{"given":"Ebbe Billmann","family":"Thorgersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rund","family":"Asvall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Storhaug","family":"Fr\u00f8ysnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Schjalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein Gunnar","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svein","family":"Dueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8ystein","family":"Fodstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom Eirik","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjersti","family":"Flatmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"issue":"1","key":"10022_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"10022_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1245\/s10434-009-0341-8","volume":"16","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Smigielski ME, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16(7):1903\u201311.","journal-title":"Ann Surg Oncol"},{"key":"10022_CR3","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12(3):703\u201327, xiii.","DOI":"10.1016\/S1055-3207(03)00048-6"},{"issue":"2","key":"10022_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jso.24290","volume":"114","author":"IS Froysnes","year":"2016","unstructured":"Froysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016;114(2):222\u20137.","journal-title":"J Surg Oncol"},{"issue":"6","key":"10022_CR5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/ijc.28158","volume":"133","author":"K Flatmark","year":"2013","unstructured":"Flatmark K, Guldvik IJ, Svensson H, et al. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer. 2013;133(6):1497\u2013506.","journal-title":"Int J Cancer"},{"issue":"8","key":"10022_CR6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/sj.bjc.6605312","volume":"101","author":"Y Andersson","year":"2009","unstructured":"Andersson Y, Engebraaten O, Fodstad O. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer. 2009;101(8):1307\u201315.","journal-title":"Br J Cancer"},{"issue":"11","key":"10022_CR7","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/bjc.2015.380","volume":"113","author":"Y Andersson","year":"2015","unstructured":"Andersson Y, Engebraaten O, Juell S, et al. Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. Br J Cancer. 2015;113(11):1548\u201355.","journal-title":"Br J Cancer"},{"key":"10022_CR8","doi-asserted-by":"crossref","unstructured":"Andersson Y, Inderberg EM, Kvalheim G, et al. Immune stimulatory effect of anti-EpCAM immunotoxin\u2014improved overall survival of metastatic colorectal cancer patients. Acta Oncol. 2020;59(4):404\u201309.","DOI":"10.1080\/0284186X.2019.1704864"},{"issue":"7","key":"10022_CR9","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1245\/s10434-017-5814-6","volume":"24","author":"IS Froysnes","year":"2017","unstructured":"Froysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the immunopeca phase 1 trial. Ann Surg Oncol. 2017;24(7):1916\u201322.","journal-title":"Ann Surg Oncol"},{"key":"10022_CR10","doi-asserted-by":"crossref","unstructured":"Froysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. Eur J Surg Oncol. 2021;47(1):134\u201338.","DOI":"10.1016\/j.ejso.2019.04.014"},{"issue":"1","key":"10022_CR11","first-page":"44","volume":"5","author":"RJ Kreitman","year":"2003","unstructured":"Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther. 2003;5(1):44\u201351.","journal-title":"Curr Opin Mol Ther"},{"issue":"12","key":"10022_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10022_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361.","journal-title":"Nat Med"},{"issue":"9","key":"10022_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1084\/jem.20120189","volume":"209","author":"E Venereau","year":"2012","unstructured":"Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209(9):1519\u201328.","journal-title":"J Exp Med"},{"key":"10022_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","volume":"220","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47\u201359.","journal-title":"Immunol Rev"},{"key":"10022_CR16","doi-asserted-by":"publisher","first-page":"172975","DOI":"10.1016\/j.ejphar.2020.172975","volume":"874","author":"MM Garcia","year":"2020","unstructured":"Garcia MM, Goicoechea C, Molina-Alvarez M, Pascual D. Toll-like receptor 4: a promising crossroads in the diagnosis and treatment of several pathologies. Eur J Pharmacol. 2020;874:172975.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10022_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1096\/fj.09-140798","volume":"24","author":"EB Thorgersen","year":"2010","unstructured":"Thorgersen EB, Hellerud BC, Nielsen EW, et al. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 2010;24(3):712\u201322.","journal-title":"FASEB J"},{"key":"10022_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.phrs.2016.06.031","volume":"111","author":"E Venereau","year":"2016","unstructured":"Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi ME. HMGB1 as biomarker and drug target. Pharmacol Res. 2016;111:534\u201344.","journal-title":"Pharmacol Res"},{"issue":"2","key":"10022_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/SLA.0b013e3181afde41","volume":"250","author":"SM Strasberg","year":"2009","unstructured":"Strasberg SM, Linehan DC, Hawkins WG. The accordion severity grading system of surgical complications. Ann Surg. 2009;250(2):177\u201386.","journal-title":"Ann Surg"},{"issue":"2","key":"10022_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.amjsurg.2008.01.021","volume":"197","author":"C Evans","year":"2009","unstructured":"Evans C, Galustian C, Kumar D, et al. Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors. Am J Surg. 2009;197(2):238\u201345.","journal-title":"Am J Surg"},{"issue":"42","key":"10022_CR21","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1097\/MD.0000000000001786","volume":"94","author":"AA Fretland","year":"2015","unstructured":"Fretland AA, Sokolov A, Postriganova N, et al. Inflammatory response after laparoscopic versus open resection of colorectal liver metastases: data from the Oslo-CoMet trial. Medicine (Baltimore). 2015;94(42):e1786.","journal-title":"Medicine (Baltimore)"},{"key":"10022_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cyto.2017.05.014","volume":"97","author":"LT Henno","year":"2017","unstructured":"Henno LT, Storjord E, Christiansen D, et al. Effect of the anticoagulant, storage time and temperature of blood samples on the concentrations of 27 multiplex assayed cytokines\u2014consequences for defining reference values in healthy humans. Cytokine. 2017;97:86\u201395.","journal-title":"Cytokine"},{"issue":"1","key":"10022_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jss.2005.01.006","volume":"126","author":"D Decker","year":"2005","unstructured":"Decker D, Tolba R, Springer W, Lauschke H, Hirner A, von Ruecker A. Abdominal surgical interventions: local and systemic consequences for the immune system\u2014a prospective study on elective gastrointestinal surgery. J Surg Res. 2005;126(1):12\u20138.","journal-title":"J Surg Res"},{"issue":"3","key":"10022_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1164\/ajrccm.150.3.8087341","volume":"150","author":"MS Dehoux","year":"1994","unstructured":"Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1994;150(3):710\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10022_CR25","first-page":"151","volume":"12","author":"JM Cavaillon","year":"2006","unstructured":"Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res. 2006;12(3):151\u201370.","journal-title":"J Endotoxin Res"},{"issue":"2","key":"10022_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10350-004-6516-2","volume":"46","author":"FP Wu","year":"2003","unstructured":"Wu FP, Sietses C, von Blomberg BM, van Leeuwen PA, Meijer S, Cuesta MA. Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. DisColon Rectum. 2003;46(2):147\u201355.","journal-title":"DisColon Rectum"},{"key":"10022_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fimmu.2018.00691","volume":"9","author":"KA Mosevoll","year":"2018","unstructured":"Mosevoll KA, Skrede S, Markussen DL, et al. Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Front Immunol. 2018;9:691.","journal-title":"Front Immunol"},{"issue":"3","key":"10022_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ijc.20371","volume":"112","author":"Y Andersson","year":"2004","unstructured":"Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer. 2004;112(3):475\u201383.","journal-title":"Int J Cancer"},{"issue":"2","key":"10022_CR29","doi-asserted-by":"publisher","first-page":"e1069938","DOI":"10.1080\/2162402X.2015.1069938","volume":"5","author":"AD Garg","year":"2016","unstructured":"Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2016;5(2):e1069938.","journal-title":"Oncoimmunology"},{"issue":"12","key":"10022_CR30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/lt.23503","volume":"18","author":"H Haugaa","year":"2012","unstructured":"Haugaa H, Thorgersen EB, Pharo A, et al. Inflammatory markers sampled by microdialysis catheters distinguish rejection from ischemia in liver grafts. Liver Transpl. 2012;18(12):1421\u20139.","journal-title":"Liver Transpl"},{"issue":"2","key":"10022_CR31","first-page":"287","volume":"1836","author":"C Billottet","year":"2013","unstructured":"Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta. 2013;1836(2):287\u201395.","journal-title":"Biochim Biophys Acta"},{"key":"10022_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10022-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T20:19:05Z","timestamp":1628367545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10022"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10022-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.D., Y.A., \u00d8.F., and K.F. are registered as inventors in a patent application owned by\u00a0Oslo University Hospital\u00a0(WO 2019\/020648) claiming various uses of the product described in this paper for cancer treatment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}